Navigation Links
Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
Date:5/24/2010

SAN MARINO, Calif., May 24 /PRNewswire/ -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the results of the clinical study entitled "Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer" at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.

STUDY SUMMARY: The goals of the Phase I/II study were to evaluate the overall safety and efficacy of intravenous infusions of Rexin-G, a tumor-targeted retrovector bearing a cytocidal anti-cyclin G1 construct, in gemcitabine-resistant pancreas cancer. A Phase II "run in" study was integrated by adaptive design wherein additional cycles were given if the patient had Grade 1 or less toxicity. Twenty patients received escalating doses of Rexin-G intravenously three times a week for four weeks. Analysis of safety showed no dose-limiting toxicity and no cumulative toxicity in patients treated up to 18 months. Analysis of efficacy in evaluable patients revealed significant tumor responses:  100% tumor control rate (TCR) was observed at all doses tested, and 24% partial response (PR) or complete response (CR) by RECIST criteria in the high dose cohorts. A dose-dependent relationship between overall survival and Rexin-G dosage was demonstrated, which was significant at the 5% statistical level by log rank test (p = 0.03). Median survival was 9.3 months and one-year survival was 33% in the high dose groups. Remarkably, one patien
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
2. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
3. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
4. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
5. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
6. Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
7. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
8. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
9. The Worlds Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers
10. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
11. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... IA (PRWEB) April 16, 2015 ... announces that the prestigious 2015 Borlaug CAST Communication ... faculty member at Tuskegee University in Alabama. Award ... written material; public presentations; and/or the use of ... in all three areas. As a specialist in ...
(Date:4/16/2015)... 16, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... PBT.U), is pleased to announce that the Company will ... 25, 2015 to be held in London, ... and Mr. James Mellon , a director ... on the key programs at its subsidiaries, Portage Pharmaceuticals ...
(Date:4/16/2015)... GUELPH, ON , April 16, 2015 /CNW/ - Bioenterprise ... opening its newest office in Charlottetown ... with the Prince Edward Island ADAPT Council for the ... are looking forward to working with PEI ADAPT.  They ... Maritimes for more than a decade," explains Dave ...
Breaking Biology Technology:The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Bioenterprise Corporation Expands into the Maritimes 2
... - 4th Quarter revenues of $22.0M increased 29% and adjusted EPS* of $0.35 ... increased 218% -, - Total ... ... Kensey Nash Corporation,(Nasdaq: KNSY ) today reported the results for its fourth quarter and ...
... and AMSTERDAM, Netherlands, Aug. 21, Paul Capital ... pharmaceutical company, today announced that they,have entered ... acquisition financing,agreement to fund SpePharm,s acquisition of ... Procter & Gamble Pharmaceuticals. At the same,time, ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading ... and marketing biopharmaceutical,products, today announced that the ... Inc. will be held on September 12, ... No.3 A1, Road 10, Shenyang Economy &,Technology ...
Cached Biology Technology:Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 21TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 2TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 3TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 4TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 53SBio Inc. to Hold Annual General Meeting 2
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... 23, 2011 University of Utah researchers have discovered a ... of the AIDS virus and inhibit it from infecting cells ... sexual transmission of the virus. Development and laboratory testing ... infection is outlined in a study set for online publication ...
... wild grazers like zebras off the grass that fattens their ... of California at Davis researchers shows that grazing by wild ... The results are published in this week,s issue of the ... managed on the premise that cattle and wildlife compete for ...
... For decades, ecologists have toiled to nail down principles ... species than others. Much of this debate is focused ... by the productivity of the habitat.Shouldn,t a patch of prairie ... or an alpine tundra? Maybe not, says an international ...
Cached Biology News:Targeting HIV's sugar coating 2Targeting HIV's sugar coating 3Zebras vs. cattle: Not so black-and-white 2Over the hump: Ecologists use power of network science to challenge long-held theory 2
... contains a precipitant to ensure that the samples ... to allow the user to follow the progress ... ABgene ® s proprietary mixture of red ... composition used in ReddyRun™ molecular weight markers. It ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
Biology Products: